Navigation Links
SuperFect Transfection Reagent

The proven activated dendrimer for transfection of a broad range of cell lines

Features and benefits
  • Fast procedure and easy handling
  • Suitable for a broad range of cell lines
  • Transfection in the presence of serum (see figure "Serum and DNA Quantity vs. Transfection Efficiency")
  • High transient and stable transfection efficiencies
  • Excellent reproducibility due to precise size and defined shape of activated dendrimers

Serum and DNA Quantity vs. Transfection Efficiency



Influence of serum and DNA quantity on transfection using SuperFect Reagent. 2 x 104 COS-7 cells were seeded per well in 96-well plates one day prior transfection. Cells were transfected using 0.12.0 g of a beta-galactosidasereporter plasmid and 3 l SuperFect Reagent per well, in either the presence or absence of serum. Each bar represents the average efficiency from four replicates assayed 48 h post-transfection.

Principle

SuperFect Reagent consists of activated-dendrimer molecules with a defined spherical architecture (1). Branches radiate from a central core and terminate at charged amino groups which can then interact with negatively charged phosphate groups of nucleic acids (see figure "Activated-Dendrimer Structure"). SuperFect Reagent assembles DNA into compact structures (see figure "SuperFectDNA Interaction") that bind to the cell surface and are taken into the cell by nonspecific endocytosis. The reagent buffers the pH of the end osome, leading to pH inhibition of endosomal nucleases, which ensures stability of SuperFectDNA complexes.

Due to highly controlled chemical synthesis the activated-dendrimer molecules in SuperFect Reagent have a precise size and a defined shape. This ensures consistent transfection-complex formation and reproducible transfection results.

Activated-Dendrimer Structure

Schematic representation of an activated dendrimer (1). Note the highly branched structure.
SuperFectDNA Interaction
Model of the SuperFectDNA complex. SuperFect Reagent (purple balls) interacts with DNA (black) to form a ring-like (toroid-like) structure. The upper right section of the illustration shows naked DNA, the lower section shows the interaction between dendrimers and DNA inside the complex, and the upper left section shows the final complete coverage of DNA within the complex. Procedure

SuperFect Transfection Reagent is provided as a ready-to-use solution. The reagent is simply added to the DNA solution, mixed, and incubated for 510 minutes to allow SuperFectDNA complexes to form. The complexes are mixed with growth medium (which can contain serum and antibiotics), and added directly to the cells. After a 23 hour incubation, a medium change is performed and the cells are incubated for expression of the transfected gene.

Applications

SuperFect Re agent is suitable for transient and stable transfection of a broad range of cell lines (see figure "Transfection of Neuronal PC-12 Cells Using SuperFect Reagent"). A searchable list of cell lines successfully transfected using SuperFect Reagent, as well as customer-developed transfection protocols, is available at the Transfection Tools web site www.qiagen.com/transfectiontools/.

Transfection of Neuronal PC-12 Cells Using SuperFect Reagent


Expression of green fluorescent protein (GFP) in differentiated PC-12 cells 5 days post-transfection. 104105 cells previously stimulated with 50 ng/ml NGF were plated per 60 mm dish one day prior to transfection. Transient transfections were performed in 2 ml low-serum growth medium (DMEM plus 0.05% FBS) using 3 g of a GFP-reporter plasmid and 15 l SuperFect Reagent. (Data kindly provided by K. Kelly-Spratt, University of Texas Southwestern Medical Center, Dallas, TX, USA.)

High-throughput transfection

The application of recombinant DNA technology to fields such as drug discovery and development has led to an increased need for high-throughput transfection. Transfection using SuperFect Reagent requires minimal handling, making it highly suitable for high-throughput screening. SuperFect Reagent provides high transfection efficiencies, excellent reproducibility, and low cytotoxicity in high-throughput transfection, and is available in bulk quantities.

Cited References

1. Tang, M.X., Redemann, C.T., and Szoka, Jr., F.C. (1996) In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjugate Chem. 7, 703.



'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
4. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
5. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
6. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
7. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
8. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
9. Efficient Transfection of Neurospora Crassa
10. Eppendorf Multiporator Transfection Protocols for Eukaryotic Cells
11. Efficient Transfection of Neurospora Crassa
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading ... (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. ... tables for its annual event, which will run from 3:00 p.m. - 8:30 ...
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces ... the secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment ... PROMPT study, which seeks to advance understanding of the hereditary risks for certain ...
(Date:2/10/2016)... ... , ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused on the discovery ... has been selected to present at the Cavendish Global Health Impact Forum taking place ... purpose of the Forum is to help family offices and foundations develop and implement ...
(Date:2/9/2016)... Feb. 9, 2016  Regenicin, Inc. (OTC Bulletin ... in the development and commercialization of regenerative cell ... and organs, recently reported the Company,s operating results ... of 2016. Lonza America , Inc. ... fiscal year in the process of consummating an ...
Breaking Biology Technology:
(Date:1/15/2016)... Rico , Jan. 15, 2016 Recent ... and small to find new ways to ensure data ... iOS and Android that ... on biometrics, transforming it into a hardware authorization token. ... users swipe their fingerprint on their KodeKey enabled device ...
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the leading ... 10,000 retail locations, web and mobile, today announced ... million from existing investors. --> ... devoted to further innovate higi,s health platform – ... web portal – including expanding services and programs ...
Breaking Biology News(10 mins):